1. Home
  2. NGNE vs UHT Comparison

NGNE vs UHT Comparison

Compare NGNE & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.99

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Universal Health Realty Income Trust

UHT

Universal Health Realty Income Trust

HOLD

Current Price

$41.19

Market Cap

628.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
UHT
Founded
2003
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
628.5M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
NGNE
UHT
Price
$35.99
$41.19
Analyst Decision
Strong Buy
Hold
Analyst Count
7
1
Target Price
$63.57
$43.00
AVG Volume (30 Days)
174.1K
83.0K
Earning Date
05-08-2026
04-27-2026
Dividend Yield
N/A
7.33%
EPS Growth
0.93
N/A
EPS
N/A
0.79
Revenue
N/A
$99,190,000.00
Revenue This Year
N/A
$2.12
Revenue Next Year
N/A
$2.94
P/E Ratio
N/A
$52.23
Revenue Growth
N/A
0.18
52 Week Low
$15.93
$35.26
52 Week High
$43.66
$46.30

Technical Indicators

Market Signals
Indicator
NGNE
UHT
Relative Strength Index (RSI) 53.66 40.36
Support Level $31.83 $38.89
Resistance Level $43.66 $43.84
Average True Range (ATR) 2.07 1.26
MACD 0.05 -0.34
Stochastic Oscillator 72.75 9.79

Price Performance

Historical Comparison
NGNE
UHT

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

Share on Social Networks: